[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
create a website
Weak Patents Are a Weak Deterrent: Patent Portfolios, the Orange Book Listing Standard, and Generic Entry in Pharmaceuticals. (2012). Sampat, Bhaven N. ; Hemphill, Scott C..
In: NBER Chapters.
RePEc:nbr:nberch:13215.

Full description at Econpapers || Download paper

Cited: 0

Citations received by this document

Cites: 32

References cited by this document

Cocites: 22

Documents which have cited the same bibliography

Coauthors: 0

Authors who have wrote about the same topic

Citations

Citations received by this document

    This document has not been cited yet.

References

References cited by this document

  1. Berndt, Ernest R., Iain M. Cockburn, and Karen A Grépin. 2006. The Impact of Incremental Innovation in Biopharmaceuticals. Drug Utilisation in Original and Supplemental Indications. PharmacoEconomics 24(2): 69-86 Branstetter, L., Chatterjee, C., Higgins, M. 2011. Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry. NBER working paper 17188.

  2. Bureau of Labor Statistics. 2010. CPI Inflation Calculator. http://www.bls.gov/data/ inflation_calculator.htm.
    Paper not yet in RePEc: Add citation now

  3. Cohen, Wesley M., Richard R. Nelson, and John P. Walsh. 2000. Protecting Their Intellectual Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (Or Not). National Bureau of Economic Research Working Paper No. 7552.

  4. Comanor, William S., and Frederic M. Scherer. 1969. Patent Statistics as a Measure of Technical Change. Journal of Political Economy 77:392–398.

  5. Deere, Carolyn. 2009. The Implementation Game. Oxford University Press.
    Paper not yet in RePEc: Add citation now

  6. DiMasi, Joseph A., Ronald W. Hansen, and Henry G. Grabowski. 2003. The Price of Innovation: New Estimates of Drug Development. Journal of Health Economics 22:151–185.

  7. Engelberg, Alfred B. 1999. Special Patent Provisions for Pharmaceuticals: Have They Outlived Their Usefulness? IDEA: The Journal of Law and Technology 39:389– 428.
    Paper not yet in RePEc: Add citation now
  8. European Commission. 2009. Final Report, Pharmaceuticals Sector Inquiry. !
    Paper not yet in RePEc: Add citation now
  9. Federal Trade Commission. 2002. Generic Drug Entry Prior to Patent Expiration.
    Paper not yet in RePEc: Add citation now
  10. Food and Drug Administration. 1985–2009. The Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
    Paper not yet in RePEc: Add citation now
  11. Frank, Richard G. 2007. The Ongoing Regulation of Generic Drugs. New England Journal of Medicine 357:1993–1996.
    Paper not yet in RePEc: Add citation now
  12. Gal, Ronny, and Shari Nikhil. 2007. Predicting Para IV: Generic Companies Have the Upper Hand in Formulation Patent Cases. Bernstein Research Report.
    Paper not yet in RePEc: Add citation now
  13. Grabowski, Henry G. 2004. Are the Economics of Pharmaceutical R&D Changing? Productivity, Patents and Political Pressures. PharmcoEconomics 22 (Supp. 2):15–24.
    Paper not yet in RePEc: Add citation now

  14. Grabowski, Henry G., and Margaret Kyle. 2007. Generic Competition and Market Exclusivity Periods in Pharmaceuticals. Managerial and Decision Economics 28:491–502.

  15. Graham, Stuart J.H., and Higgins, Matthew J. 2007. Comanor and Scherer Revisited: Do Patents Proxy for New Product Innovations? Working Paper.
    Paper not yet in RePEc: Add citation now
  16. Hemphill, C. Scott and Bhaven N. Sampat. 2011b. Evergreening, Patent Challenges, and Effective Market Life in Pharmaceuticals. Working Paper, http://ssrn.com/abstract=1830404.
    Paper not yet in RePEc: Add citation now

  17. Hemphill, C. Scott, and Bhaven N. Sampat. 2011a. When Do Generics Challenge Drug Patents? Journal of Empirical Legal Studies 8:613-649.

  18. Hemphill, C. Scott. 2006. Paying for Delay: Pharmaceutical Patent Settlement as a Regulatory Design Problem. New York University Law Review 81:1553–1623.
    Paper not yet in RePEc: Add citation now
  19. Hemphill, C. Scott. 2009. An Aggregate Approach to Antitrust: Using New Data and Rulemaking to Preserve Drug Competition. Columbia Law Review 109:629–688.
    Paper not yet in RePEc: Add citation now
  20. Higgins, Matthew J., and Stuart J.H. Graham. 2009. Balancing Innovation and Access: Patent Challenges Tip the Scales. Science 326:370–371.
    Paper not yet in RePEc: Add citation now
  21. IMS Institute for Healthcare Informatics, 2011. The Use of Medicines in the United States: Review of 2010.
    Paper not yet in RePEc: Add citation now
  22. Lemley, Mark A. 2001. Rational Ignorance at the Patent Office. Northwestern University Law Review 95:1495–1532. !
    Paper not yet in RePEc: Add citation now

  23. Levin, Richard C., Alvin K. Klevorick, Richard R. Nelson, and Sidney G. Winter. 1987. Appropriating the Returns from Industrial Research and Development. Pp. 783– 832 in Brookings Papers on Economic Activity (Special Issue).

  24. Murphy, Kevin, and Robert Topel. 2000. Measuring the Gains from Medical Research: An Economic Approach. Chicago, Ill: University of Chicago Press.
    Paper not yet in RePEc: Add citation now
  25. Roin, Benjamin N. 2009. Unpatentable Drugs and the Standard of Patentability. Texas Law Review 87:503-570.
    Paper not yet in RePEc: Add citation now
  26. Rumore, Martha M. 2007. Patent Law, Trademarks and Copyrights. In Delbert D. Konnor, Pharmacy Law, Desk Reference (125-143). Haworth Press.
    Paper not yet in RePEc: Add citation now

  27. Scott Morton, Fiona. 1999. Entry Decisions in the Generic Pharmaceutical Industry. Rand Journal of Economics 30:421–440.

  28. Shapiro, Carl. 2003. Antitrust Limits to Patent Settlements. Rand Journal of Economics 34:391–411.

  29. Thomas, John R. 2005. Pharmaceutical Patent Law. Washington, D.C.: BNA Books.
    Paper not yet in RePEc: Add citation now
  30. Thomas, John R. 2009. Patent “Evergreening”: Issues in Innovation and Competition.
    Paper not yet in RePEc: Add citation now
  31. Voet, Martin A. 2005. The Generic Challenge: Understanding Patents, FDA and Pharmaceutical Life-Cycle Management. Boca Raton, Fla.: Brown Walker Press.
    Paper not yet in RePEc: Add citation now
  32. Wertheimer, Albert I., and Thomas. M. Santella. 2005. Pharmacoevolution: the advantages of incremental innovation. IPN Working Papers on Intellectual Property, Innovation and Health.
    Paper not yet in RePEc: Add citation now

Cocites

Documents in RePEc which have cited the same bibliography

  1. The Unexpected Consequences of Generic Entry. (2019). Ornaghi, Carmine ; Castanheira, Micael ; Siotis, Georges ; de Moura, Micael Castanheira .
    In: ULB Institutional Repository.
    RePEc:ulb:ulbeco:2013/298643.

    Full description at Econpapers || Download paper

  2. The unexpected consequences of generic entry. (2019). Siotis, Georges ; Ornaghi, Carmine ; Castanheira, Micael.
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:68:y:2019:i:c:s0167629618305332.

    Full description at Econpapers || Download paper

  3. The Unexpected Consequences of Generic Entry. (2019). Siotis, Georges ; Ornaghi, Carmine ; Castanheira, Micael.
    In: Working Papers ECARES.
    RePEc:eca:wpaper:2013/293928.

    Full description at Econpapers || Download paper

  4. Why do HMOs spend less? Patient selection, physician price sensitivity, and prices. (2018). Sacks, Daniel W.
    In: Journal of Public Economics.
    RePEc:eee:pubeco:v:168:y:2018:i:c:p:146-161.

    Full description at Econpapers || Download paper

  5. The Unexpected Consequences of Asymmetric Competition. An Application to Big Pharma. (2017). Siotis, Georges ; Ornaghi, Carmine ; Castanheira, Micael ; de Frutos, Maria-Angeles .
    In: CEPR Discussion Papers.
    RePEc:cpr:ceprdp:11813.

    Full description at Econpapers || Download paper

  6. Accounting for Price Endogeneity in Airline Itinerary Choice Models: An Application to Continental U.S. Markets. (2016). Higgins, Matthew ; Schyns, Michael ; Newman, Jeffrey P ; Garrow, Laurie A ; Lurkin, Virginie.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:22730.

    Full description at Econpapers || Download paper

  7. Are Settlements in Patent Litigation Collusive? Evidence from Paragraph IV Challenges. (2016). Seabury, Seth ; Helland, Eric.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:22194.

    Full description at Econpapers || Download paper

  8. Parallel Trade of Pharmaceuticals: The Danish Market for Statins. (2016). Mendez, Susan J.
    In: Melbourne Institute Working Paper Series.
    RePEc:iae:iaewps:wp2016n8.

    Full description at Econpapers || Download paper

  9. Parallel Trade of Pharmaceuticals: The Danish Market for Statins. (2016). Mendez, Susan J.
    In: Melbourne Institute Working Paper Series.
    RePEc:iae:iaewps:wp2016n08.

    Full description at Econpapers || Download paper

  10. The impact of advance purchase deadlines on airline consumers’ search and purchase behaviors. (2015). Castillo, Marco ; Higgins, Matthew J ; Hotle, Susan L ; Garrow, Laurie A.
    In: Transportation Research Part A: Policy and Practice.
    RePEc:eee:transa:v:82:y:2015:i:c:p:1-16.

    Full description at Econpapers || Download paper

  11. The consumer welfare implications of governmental policies and firm strategy in markets for medicines. (2015). Kubo, Kensuke ; Pingali, Viswanath ; Chatterjee, Chirantan.
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:44:y:2015:i:c:p:255-273.

    Full description at Econpapers || Download paper

  12. The welfare impact of parallel imports: A structural approach applied to the German market for oral antidiabetics. (2014). Suppliet, Moritz ; Herr, Annika ; Duso, Tomaso.
    In: Annual Conference 2014 (Hamburg): Evidence-based Economic Policy.
    RePEc:zbw:vfsc14:100298.

    Full description at Econpapers || Download paper

  13. The Welfare Impact of Parallel Imports: A Structural Approach Applied to the German Market for Oral Anti-diabetics. (2014). Suppliet, Moritz ; Herr, Annika ; Duso, Tomaso.
    In: Health, Econometrics and Data Group (HEDG) Working Papers.
    RePEc:yor:hectdg:14/09.

    Full description at Econpapers || Download paper

  14. THE WELFARE IMPACT OF PARALLEL IMPORTS: A STRUCTURAL APPROACH APPLIED TO THE GERMAN MARKET FOR ORAL ANTI‐DIABETICS. (2014). Suppliet, Moritz ; Herr, Annika ; Duso, Tomaso.
    In: Health Economics.
    RePEc:wly:hlthec:v:23:y:2014:i:9:p:1036-1057.

    Full description at Econpapers || Download paper

  15. The Welfare Impact of Parallel Imports: A Structural Approach Applied to the German Market for Oral Anti-Diabetics. (2014). Suppliet, Moritz ; Herr, Annika ; Duso, Tomaso.
    In: Discussion Papers of DIW Berlin.
    RePEc:diw:diwwpp:dp1373.

    Full description at Econpapers || Download paper

  16. Pharmaceutical Followers. (2013). Ridley, David ; Ellickson, Paul ; Landry, Peter ; Arcidiacono, Peter .
    In: NBER Working Papers.
    RePEc:nbr:nberwo:19522.

    Full description at Econpapers || Download paper

  17. The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales Following Loss of Exclusivity. (2013). Cockburn, Iain ; Bosworth, Barry ; Frank, Richard ; Aitken, Murray L. ; Kleinrock, Michael ; Berndt, Ernst R. ; Shapiro, Bradley T..
    In: NBER Working Papers.
    RePEc:nbr:nberwo:19487.

    Full description at Econpapers || Download paper

  18. The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales following Loss of Exclusivity. (2013). Bosworth, Barry ; Frank, Richard ; Aitken, Murray L. ; Kleinrock, Michael ; Cockburn, Iain ; Berndt, Ernst R. ; Shapiro, Bradley.
    In: NBER Chapters.
    RePEc:nbr:nberch:13094.

    Full description at Econpapers || Download paper

  19. Pharmaceutical followers. (2013). Ridley, David ; Landry, Peter ; Arcidiacono, Peter ; Ellickson, Paul B..
    In: International Journal of Industrial Organization.
    RePEc:eee:indorg:v:31:y:2013:i:5:p:538-553.

    Full description at Econpapers || Download paper

  20. Entry in the ADHD drugs market: Welfare impact of generics and me-toos. (2013). Bokhari, Farasat ; Farasat A. S. Bokhari, ; Fournier, Gary M..
    In: Journal of Industrial Economics.
    RePEc:bla:jindec:v:61:y:2013:i:2:p:339-392.

    Full description at Econpapers || Download paper

  21. Weak Patents Are a Weak Deterrent: Patent Portfolios, the Orange Book Listing Standard, and Generic Entry in Pharmaceuticals. (2012). Sampat, Bhaven N. ; Hemphill, Scott C..
    In: NBER Chapters.
    RePEc:nbr:nberch:13215.

    Full description at Econpapers || Download paper

  22. Evergreening, patent challenges, and effective market life in pharmaceuticals. (2012). Sampat, Bhaven N. ; Hemphill, Scott C..
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:31:y:2012:i:2:p:327-339.

    Full description at Econpapers || Download paper

Coauthors

Authors registered in RePEc who have wrote about the same topic

Report date: 2024-12-26 03:55:33 || Missing content? Let us know

CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated October, 6 2023. Contact: CitEc Team.